Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Prohibited at all times
2026: prohibited at all times (S2). [1]
2026 List, S2.2.4, printed page 8 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Identity and medical context
GHRP-2 is also called pralmorelin. Japan’s PMDA label describes pralmorelin hydrochloride as a prescription diagnostic agent for evaluating growth-hormone deficiency. That narrow medical use is not approval for general muscle gain or recovery, and does not grant sport permission. The label includes contraindications and adverse reactions such as pregnancy restrictions, warmth, gastrointestinal symptoms and low blood pressure. [2]
Acute human research
In a randomized, blinded crossover experiment, seven lean healthy men received GHRP-2 or saline on separate study days. Food intake, hunger and growth-hormone responses increased under the study conditions. The experiment did not test long-term muscle gain, athletic performance or injury healing. Absence of reported side effects in this tiny acute experiment cannot establish chronic safety. [3]
Risks and supplement exposure
FDA notes peptide-quality and immunogenicity concerns. Serious events reported in ill patients include altered insulin requirements, infection, pancreatitis and deaths, but a causal link to GHRP-2 was not established. [4]
A 2010 analytical study identified GHRP-2 in tablets marketed as a nutritional supplement. This confirms a historical product exposure, not the prevalence of GHRP-2 across supplements or the contents of a current batch. [5]
What remains uncertain
- The Japanese label is paraphrased in English, not reproduced as an official translation.
- The supplement paper was available at abstract depth only.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · official_full_text_relevant_sections
Effective date; S0 printed page 4; S2 printed pages 7–8
- PMDA: GHRP KAKEN injection, pralmorelin hydrochloride, July 2025 label ↗Accessed 2026-11-10 · official_full_text_relevant_sections
Indications, pharmacology, contraindications and adverse reactions
- Laferrère et al. 2005: GHRP-2 and food intake in healthy men ↗Accessed 2026-11-10 · full_text_relevant_sections
JCEM; DOI 10.1210/jc.2004-1719; methods, results and limitations
- FDA: bulk substances that may present significant compounding safety risks ↗Accessed 2026-11-10 · official_full_text_relevant_sections
GHRP-2 and GHRP-6 entries
- Thomas et al. 2010: identification of GHRP-2 in a nutritional supplement ↗Accessed 2026-11-10 · abstract_only
Institutional abstract; DOI 10.1002/dta.120
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.